Skip to content

MDMA research published in 2020

Page 3 of 4: studies 41 to 60 of 66, newest first. Back to the MDMA overview

Studies

Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Neural Regeneration Research May 1, 2020 Giulia Costa, Maria Antonietta De Luca, Gessica Piras et al.

Preclinical and clinical studies indicate that synthetic psychoactive substances, in addition to having abuse potential, may elicit toxic effects of varying severity at the peripheral and central levels. Nowadays, toxicity induced by synthetic psychoactive substances poses a serious harm for health, since recreational use of these substances is on the rise among young and adult people. The...

Spinal cord injury after the use of ecstasy in a young male.

Spinal cord series and cases April 28, 2020 Myrna Elena Kastaneer, Maria Christina Maijers, Juan David Martina

Ecstasy is a commonly used party drug and is the second most popular drug after marijuana among youngsters. Serious health hazards have been described including cardiac diseases, neurological complications, multi-organ failure, and even death. Spinal cord injury/dysfunction (SCI/D) is rarely described as a result of ecstasy ingestion. We present a case of a 19-year-old male patient who was...

Lysosomal Dysfunction and Autophagy Blockade Contribute to MDMA-Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells.

Chemical Research in Toxicology April 20, 2020 I-Hsun Li, Jui-Hu Shih, Ting-Yin Yeh et al.

Methylenedioxymethamphetamine (MDMA) is a psychostimulant with high abuse potential and severe neurotoxicity. According to our previous study, MDMA promotes autophagosome accumulation and contributes to cell death in cultured cortical and serotonergic neurons. However, the detailed mechanism underlying autophagy dysfunction remains unclear. Lysosomes play an important role in autophagic...

Psychedelics for Psychiatric Disorders: More Research Needed

Psychiatric News April 13, 2020 Nick Zagorski

Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsychedelics for Psychiatric Disorders: More Research NeededNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:13 Apr 2020https://doi.org/10.1176/appi.pn.2020.4a14AbstractAPA’s Work Group on Biomarkers and Novel Treatments suggests that psychedelic drug trials need more standard...

“They are not the words of a rational man”: ecstatic prophecy in Montanism

April 6, 2020 Maria Dell’Isola 2 citations

Both the historiographical analysis and the ancient documents about the Christian movement known as Montanism place paramount importance on prophecy, visions, and ecstasy. The theological refutation of Montanist teaching and doctrine in the heresiological sources was almost entirely shaped by the attribution of deceitfulness and error to the experience of ecstatic prophecy. Even though some...

MDMA and TAAR1‐mediated RhoA Activation in Serotonin Neurons

The FASEB Journal April 1, 2020 Suzanne Underhill, Susan Amara

We have recently described the biochemical cascade through which the psychostimulant amphetamine leads to internalization of the dopamine and norepinephrine transporters, (DAT and NET). Amphetamine is a relatively high affinity substrate for DAT and NET and they both serve as efficient conduits for amphetamine entry into the cell. Once inside the cell, amphetamine activates the trace amine...

Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine.

Pharmacology, Biochemistry, and Behavior April 2020 Dawn E Muskiewicz, Federico Resendiz-Gutierrez, Omar Issa et al.

Synthetic psychoactive cathinones (SPCs) are drugs with psychostimulant and entactogenic properties like methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA). Despite clinical reports of human overdose, it remains to be determined if SPCs have greater propensity for adverse effects than MA or MDMA. To determine whether the SPCs cathinone (CAT), methcathinone (MCAT), mephedrone...

Antibody Gene Therapy Mitigates Adverse Immunological Effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in Male BALB/c Mice

The FASEB Journal April 1, 2020 Chris Bolden, Cameron Tilley, Charles E Hay et al.

3,4‐Methylenedioxymethamphetamine (MDMA) is a popular recreational psychostimulant and hallucinogen typically used in “rave” settings. Despite the “positive” feelings sometimes associated with its use, there are toxicities that accompany its use. In the periphery, MDMA causes immunosuppression that can make users more susceptible to infection. Conversely, in the CNS MDMA initiates a...

3,4-Methylenedioxymethamphetamine (MDMA) - Assisted psychotherapy for treatment of posttraumatic stress disorder: Literature review

Romanian Journal of Psychiatry & Psychotherapy March 31, 2020 Tiberiu Constantin Ionescu, Ionut-Stelian Popa, Alin Chiriac et al.

Objectives Post-traumatic stress disorder (PTSD) is a severe psychiatric disorder, with disabling potential and chronic evolution, that occurs at some people due to exposure to a specific traumatic event or threats of death, serious injury or sexual violence. Currently, psychotherapy is accepted as one of the most effective methods of treating PTSD. Incomplete clinical response as well as...

DOI: 10.37897/rjpp.2020.1.3 (opens in new tab) MDMA Addiction Psychotherapist Posttraumatic stress +1

MDMA interactions with pharmaceuticals and drugs of abuse

Expert Opinion on Drug Metabolism & Toxicology March 31, 2020 Esther Papaseit, Clara Pérez‐mañá, Marta Torrens et al. 34 citations

Introduction: MDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, has become one of the most widely used recreational psychostimulant drugs in the world. Among recreational ecstasy/MDMA users, polydrug use is a phenomenon whose common purpose is to experience the synergistic effect of the combined drugs, moderate MDMA effects, prevent potential toxicity, enhance...

Can Psychedelics Radically Change SUD Treatment?

Psychiatric News March 20, 2020 Katie O’connor

Though the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research persist. Researchers around the world are investigating how drugs such as LSD, MDMA (also known as ecstasy), ketamine, and psilocybin (the active ingredient in magic mushrooms) can treat patients with substance use disorders (SUD). Though there is still a lot to learn, early...

NBOMes–Highly Potent and Toxic Alternatives of LSD

Frontiers in Neuroscience February 26, 2020 Monika Kacela, Piotr Adamowicz, Jolanta B. Zawilska 79 citations

Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a N-(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and...

Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder

Journal of Traumatic Stress February 19, 2020 Ingmar Gorman, Alexander Belser, Lisa Jerome et al. 43 citations Expression of concern

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but posttraumatic growth (PTG), which consists of positive changes in self‐perception, interpersonal relationships, or philosophy of life, has not been studied with this treatment. Participant data ( n = 60) were pooled...

DOI: 10.1002/jts.22479 (opens in new tab) MDMA Placebo Posttraumatic stress Posttraumatic growth +3

A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

Journal of the Neurological Sciences January 31, 2020 Tingying Chi, Jessica A. Gold 95 citations

Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The purpose of this review is to...

Case of Cardiac Arrest Treated with Extra-Corporeal Life Support after MDMA Intoxication

Case Reports in Critical Care January 26, 2020 Pierre Voizeux, Romain Lewandowski, Theresa Daily et al. 7 citations

Objective. To describe the case of a patient who developed a serotonin syndrome due to a 3,4-methylenedioxymethamphetamine ingestion with electrical storm and refractory cardiac arrest. Design. Case report. Study Selection. ICU of a university hospital. Patient. A 22-year-old man transferred to the emergency room with hyperthermia, tremors, and mydriasis presented a cardiac arrest due to...

Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing

Neuropsychopharmacology January 24, 2020 Carla Agurto, Guillermo Cecchi, Raquel Norel et al. 33 citations

Abstract The detection of changes in mental states such as those caused by psychoactive drugs relies on clinical assessments that are inherently subjective. Automated speech analysis may represent a novel method to detect objective markers, which could help improve the characterization of these mental states. In this study, we employed computer-extracted speech features from multiple domains...

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Frontiers in Psychiatry January 22, 2020 Earth Erowid, Fire Erowid, Albert Garcia‐romeu et al. 155 citations

While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD.

In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation.

Drug and Alcohol Dependence January 13, 2020 Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.

BACKGROUND Recent clinical studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct treatment for posttraumatic stress disorder (PTSD). Despite these promising findings, MDMA administration in controlled settings can increase blood pressure, heart rate, and body temperature. Previous studies indicate thatO-demethylated metabolites of MDMA contribute to its adverse...

Multivisceral Failure in a Context of Serotonin Syndrome Induced by MDMA: The Investigation of a Unique and Nationwide Network.

Journal of Addiction Medicine 2020 Elise Humeau, Hugo Peyre, Gregory Pfau et al.

: The occasional ingestion of 3,4-methylenedioxy-N-methylamphetamine (MDMA) presents serious risks of side effects including death through multivisceral failure in a context of serotonin syndrome. The significant increasing evolution of illicit MDMA street dosages over the past 2 decades and the difficulty for physicians to know what quantity the patients may have consumed, make MDMA a drug...

Diffusion of Ecstasy in the Electronic Dance Music Scene.

Substance Use & Misuse 2020 Joseph J Palamar

Ecstasy (MDMA, Molly) is among the most prevalent drugs used by people who attend electronic dance music (EDM) events; however, little recent research has examined diffusion of ecstasy in this high-risk population. Methods: 1,020 EDM event-attending adults (aged 18-40) were surveyed in NYC in 2018 using time-spacing sampling. Participants were asked about past-year ecstasy use, and those...